Saunders, co-founder at Intellihealth and assistant professor of Clinical Medicine at Weill Cornell Medical College, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.
The benefits of addressing barriers and increasing access to HIV PrEP therapies to high-risk populations across the globe.
Types of patients who will likely benefit from long-acting injectable PrEP therapies in the HIV treatment pipeline.
An overview of HIV PrEP therapies in the pipeline and their potential roles as they are introduced into the community for use among high-risk populations.
Updates to the US Preventive Services Task Force grade A recommendation for HIV PrEP therapy and payer response to supporting providers and pharmacists who prescribe therapies used as prophylaxis.
An expert in endocrinology reviews updates from the AMCP Nexus 2021 conference on treatment persistence and adherence with iGlarLixi versus free-dose combinations of basal insulin and GLP-1 receptor agonists, and shares insight on future directions for disease management.
Rodolfo J. Galindo, MD, comments on the benefits of fixed-ratio combination therapies for the management of type 2 diabetes compared with premixed insulin.
Strategies that can help address disparities in care for patients with HIV and reach high-risk groups of patients to ensure access to screening and PrEP.
The advantages of coordinated care between multiple health care providers when managing patients on HIV PrEP therapy.
In the final part of a two-part video series, Wes Gilson, senior director MR of Business Development at Siemens Healthineers, advises how payers and health facilities can help improve patient access to MRI care, and shares some MRI alternatives.
In this first part of a two-part video series, Wes Gilson, senior director MR of Business Development at Siemens Healthineers, addresses why improving access to magnetic resonance imaging (MRI) is crucial to advancing health equity, and what barriers are limiting that access to patients.
A key opinion leader reviews clinical data for newly approved injectable medications, iGlarLixi and iDegLira, for the management of type 2 diabetes as seen in the LixiLan-O and DUAL studies.
Rodolfo J. Galindo, MD, provides insight on the benefit of fixed-ratio combinations of basal insulin and GLP1 agonists for the optimal management of type 2 diabetes.
Discussion regarding HIV PrEP walkaway rates and strategies that can help support patients and increase adherence to therapy.
Recommendations when talking with patients about goals of HIV PrEP and ensuring a patient-centered approach to care.
Dr Al-Hendy discusses the impact UF has on a patient’s life and their typical patient journey through the healthcare system.
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP, provides a comprehensive background on uterine fibroids, explaining everything from clinical burden to symptoms.
Payer perspective regarding strategies that can be deployed to help improve the patient/provider experience and utilization of PrEP therapy as prophylaxis against HIV.
The financial burden associated with HIV and the potential effects of PrEP uptake on overall costs of care.
Considerations to help identify and increase utilization of PrEP therapy among patients who are eligible for treatment.
Dr Jennifer Brigitte Green considers the patient selection for fixed-ratio combinations of basal insulin and GLP-1 receptor agonists among patients with type 2 diabetes and provides insight around Medicare patient access to insulin and injectable medications.
Jennifer Brigitte Green, MD, discusses the reasoning behind clinical inertia in treating patients with type 2 diabetes and comments on achieving and maintaining glycemic control over an extended period.
Dr Jennifer Brigitte Green addresses clinical considerations for patients with type 2 diabetes who are not responding to their oral antidiabetic agents and discusses her strategy for insufficient target glycemic control with insulin regimens.
Closing out his discussion on CGP, David Gandara, MD, looks toward future opportunities for CGP in screening patients before or after surgery.
Considering the value of comprehensive genomic profiling, David Gandara, MD, highlights the importance of supporting access to testing.
A brief discussion on the value of commercially available comprehensive genomic profiling over homegrown testing.
In this interview, Briana Contreras, associate editor of Managed Healthcare Executive, spoke with Shara Cohen, CEO of Carallel, an organization built to support caregivers. Cohen not only spoke about who caregivers are and the vital role they play in healthcare, but the challenges they face. She also discussed ways health plans can do better to meet the needs of today’s caregivers.
David Gandara, MD, explains how the scope of comprehensive genomic profiling has shifted from a select few patients to the majority.
A review of how comprehensive genomic profiling can better inform treatment planning and alleviate health care economic burden.
Current strategies used to evaluate the performance of therapies used to treat atopic dermatitis and guide formulary decisions, and recommendations to help patients receive access to effective therapies.
